Back

Outcomes of atrial functional substrate mapping based ablation detected by isochronal late activation mapping in addition to pulmonary vein isolation in atrial fibrillation

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Atrial substrate mapping Rhythm Control, Catheter Ablation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Can Menemencioglu

Sorgun State Hospital, Yozgat (Turkiye)

6 More presentations in this session

Presentation thumbnail
Bi-atrial substrate characterization in cardiac amyloidosis: a comparative analysis of AL and ATTR forms and implications for ablation of atrial fibrillation
Doctor J. Huisl (Giessen, DE)
Abstract Slides Video
Presentation thumbnail
Identification of the mapping-based voltage-derived parameter for accurate arrhythmia outcome prediction in patients undergoing first PVI
Doctor T. Huang (Lucerne, CH)
Abstract Slides Video
Presentation thumbnail
Identification of low-voltage areas during atrial fibrillation: a unipolar, bipolar and omnipolar perspective
Assistant Professor M. Van Schie (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Endocardial low voltage areas have a significantly reduced success rate after ablation of persistent atrial fibrillation: a prospective randomized trial
Doctor B. Kaiser (Stuttgart, DE)
Abstract Slides Video
Presentation thumbnail
Dynamic left atrial substrate in patients undergoing redo ablation for atrial fibrillation recurrence
Doctor A. Spadotto (Bologna, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Atrial substrate mapping

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Presentation
Atrial functional substrate mapping predicts the critical isthmus of left atrial reentrant tachycardia in atrial fibrillation
thumbnail
Congress Presentation
Temporal dynamics of deceleration zones during S3 isochronal mapping-guided VT ablation
thumbnail
Congress Presentation
Ultra-low voltage zones as a marker of atrial cardiomyopathy: insights from high-density mapping

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources